These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19084536)

  • 1. Effects of CpG methylation on recognition of DNA by the tumour suppressor p53.
    Petrovich M; Veprintsev DB
    J Mol Biol; 2009 Feb; 386(1):72-80. PubMed ID: 19084536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unveiling the methylation status of CpG dinucleotides in the substituted segment of the human p53 knock-in (Hupki) mouse genome.
    Kim SI; Hollstein M; Pfeifer GP; Besaratinia A
    Mol Carcinog; 2010 Dec; 49(12):999-1006. PubMed ID: 20945503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene.
    Schroeder M; Mass MJ
    Biochem Biophys Res Commun; 1997 Jun; 235(2):403-6. PubMed ID: 9199206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation and deamination of CpGs generate p53-binding sites on a genomic scale.
    Zemojtel T; Kielbasa SM; Arndt PF; Chung HR; Vingron M
    Trends Genet; 2009 Feb; 25(2):63-6. PubMed ID: 19101055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation.
    Pogribny IP; James SJ
    Cancer Lett; 2002 Feb; 176(2):169-74. PubMed ID: 11804744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of acute dichlorodiphenyltrichloroethane exposure on hypermethylation status and down-regulation of p53 and p16INK4a genes in rat liver.
    Kostka G; Urbanek-Olejnik K; Liszewska M; Winczura A
    Environ Toxicol; 2016 May; 31(5):584-92. PubMed ID: 25410620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylated CpG dinucleotides are the preferential targets for G-to-T transversion mutations induced by benzo[a]pyrene diol epoxide in mammalian cells: similarities with the p53 mutation spectrum in smoking-associated lung cancers.
    Yoon JH; Smith LE; Feng Z; Tang M; Lee CS; Pfeifer GP
    Cancer Res; 2001 Oct; 61(19):7110-7. PubMed ID: 11585742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB and SP1 transcription factors.
    Mancini DN; Singh SM; Archer TK; Rodenhiser DI
    Oncogene; 1999 Jul; 18(28):4108-19. PubMed ID: 10435592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping the methylation pattern by bisulfite genomic sequencing of the E-cadherin promoter CpG island in nasopharyngeal carcinoma.
    Kao RH; Huang LC; Hsu YH
    Anticancer Res; 2002; 22(6C):4109-13. PubMed ID: 12553040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation.
    Nguyen CT; Gonzales FA; Jones PA
    Nucleic Acids Res; 2001 Nov; 29(22):4598-606. PubMed ID: 11713309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All and only CpG containing sequences are enriched in promoters abundantly bound by RNA polymerase II in multiple tissues.
    Rozenberg JM; Shlyakhtenko A; Glass K; Rishi V; Myakishev MV; FitzGerald PC; Vinson C
    BMC Genomics; 2008 Feb; 9():67. PubMed ID: 18252004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypermethylation of growth arrest DNA damage-inducible gene 45 beta promoter in human hepatocellular carcinoma.
    Qiu W; Zhou B; Zou H; Liu X; Chu PG; Lopez R; Shih J; Chung C; Yen Y
    Am J Pathol; 2004 Nov; 165(5):1689-99. PubMed ID: 15509538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells.
    Nguyen C; Liang G; Nguyen TT; Tsao-Wei D; Groshen S; Lübbert M; Zhou JH; Benedict WF; Jones PA
    J Natl Cancer Inst; 2001 Oct; 93(19):1465-72. PubMed ID: 11584062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors.
    Stirzaker C; Millar DS; Paul CL; Warnecke PM; Harrison J; Vincent PC; Frommer M; Clark SJ
    Cancer Res; 1997 Jun; 57(11):2229-37. PubMed ID: 9187126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CpG Dinucleotide Adjacent to a κB Site Affects NF-κB Function through Its Methylation.
    Wang T; Li J; Ding K; Zhang L; Che Q; Sun X; Dai Y; Sun W; Bao M; Wang X; Yang L; Li Z
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytosine methylation determines hot spots of DNA damage in the human P53 gene.
    Denissenko MF; Chen JX; Tang MS; Pfeifer GP
    Proc Natl Acad Sci U S A; 1997 Apr; 94(8):3893-8. PubMed ID: 9108075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients.
    Agirre X; Vizmanos JL; Calasanz MJ; García-Delgado M; Larráyoz MJ; Novo FJ
    Oncogene; 2003 Feb; 22(7):1070-2. PubMed ID: 12592393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A PCR-based method for studying DNA methylation.
    Ariel M
    Methods Mol Biol; 2001; 181():205-16. PubMed ID: 12843452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA.
    Veprintsev DB; Fersht AR
    Nucleic Acids Res; 2008 Mar; 36(5):1589-98. PubMed ID: 18234719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.